Afabicin - Debiopharm

Drug Profile

Afabicin - Debiopharm

Alternative Names: AFN 1720; AFN-1252-prodrug; Debio 1450; Debio-1452-prodrug

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affinium Pharmaceuticals
  • Developer Debiopharm Group
  • Class Anti-infectives; Benzofurans; Naphthyridines; Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteomyelitis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Skin and soft tissue infections
  • Phase I Bone and joint infections
  • No development reported Staphylococcal infections

Most Recent Events

  • 06 Oct 2017 Debiopharm completes a phase I drug-drug interaction trial in Healthy volunteers in United Kingdom (PO) (NCT03209648)
  • 28 Jul 2017 Chemical structure information added
  • 07 Jul 2017 No development reported - Phase-I for Staphylococcal infections (In volunteers) in USA (PO; Tablet, Liquid, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top